Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy — Stella

Home/Amyloid Cardiomyopathy/

View on ClinicalTrials.gov

Recruiting

Back to Amyloid Cardiomyopathy trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Canada

London Regional Health Science Centre, London, Ontario

Key details

Phase

Early testing / Safety & dosing

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Collaborators

Greenstone Biosciences, Stanford University

Enrollment target

~20 participants

Started

September 2024

Primary completion

September 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

Age range

40 Years – 80 Years

Last updated June 2025